Genomic Insights for Personalized Care: Motivating At-Risk Individuals Toward Evidence-Based Health Practices

Tony Chen[1,*], Giang Pham[2], Louis Fox[2], Nina Adler[3,4], Xiaoyu Wang[5,6], Jingning Zhang[7], Jinyoung Byun[8], Younghun Han[8] Gretchen R.B. Saunders[9], Dajiang Liu[10], Michael J. Bray[11,12], Alex T. Ramsey[2], James McKay[13], Laura Bierut[2], Christopher I. Amos[7,14], Rayjean J. Hung[4], Xihong Lin[1,15], Haoyu Zhang[5,†,*], Li-Shiun Chen[2,†,*]

[1] Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
[2] Department of Psychiatry, Washington University School of Medicine, St. Louis, USA
[3] Department of Anthropology, University of Toronto, Mississauga, ON, Canada
[4] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, and University of Toronto, Toronto, Canada
[5] Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
[6] Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Rockville, MD, USA
[7] Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
[8] Department of Medicine, Section of Epidemiology and Population Science, Institute for Clinical and Translational Research, Houston, TX, USA
[9] Department of Psychology, University of Minnesota, Minneapolis, MN, USA
[10] Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA
[11] Department of Genetic Counseling, Bay Path University, Longmeadow, MA, USA
[12] ThinkGenetics, Inc, USA
[13] International Agency for Research on Cancer, World Health Organization, Lyon, France
[14] Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA
[15] Department of Statistics, Harvard University, Cambridge, USA

*Correspondence to: Tony Chen (tonychen@g.harvard.edu), Haoyu Zhang (haoyu.zhang2@nih.gov) and Li-Shiun Chen (li-shiun@wustl.edu).
†These authors jointly supervised this work: Haoyu Zhang and Li-Shiun Chen.

Abstract

Background: Lung cancer and tobacco use pose significant global health challenges,

necessitating a comprehensive translational roadmap for improved prevention

strategies. Polygenic risk scores (PRSs) are powerful tools for patient risk stratification

but have not yet been widely used in primary care for lung cancer, particularly in diverse

patient populations.

Methods: We propose the GREAT care paradigm, which employs PRSs to stratify

disease risk and personalize interventions. We developed PRSs using large-scale multi-

ancestry genome-wide association studies and standardized PRS distributions across

all ancestries. We applied our PRSs to 796 individuals from the GISC Trial, 350,154

from UK Biobank (UKBB), and 210,826 from All of Us Research Program (AoU), totaling

561,776 individuals of diverse ancestry.

Results: Significant odds ratios (ORs) for lung cancer and difficulty quitting smoking

were observed in both UKBB and AoU. For lung cancer, the ORs for individuals in the

highest risk group (top 20% versus bottom 20%) were 1.85 (95% CI: 1.58 – 2.18) in

UKBB and 2.39 (95% CI: 1.93 – 2.97) in AoU. For difficulty quitting smoking, the ORs

(top 33% versus bottom 33%) were 1.36 (95% CI: 1.32 – 1.41) in UKBB and 1.32 (95%

CI: 1.28 – 1.36) in AoU.

Conclusion: Our PRS-based intervention model leverages large-scale genetic data for

robust risk assessment across populations. This model will be evaluated in two cluster-

randomized clinical trials aimed at motivating health behavior changes in high-risk

patients of diverse ancestry. This pioneering approach integrates genomic insights into

primary care, promising improved outcomes in cancer prevention and tobacco treatment.

Introduction

The worldwide burden of lung cancer and tobacco smoking presents major challenges to global health[1]. Evidence-based practices to reduce their risk such as cancer screening and tobacco treatment (e.g. smoking cessation medication) have long existed but are infrequently used in most primary care practices. Communication of the precision risk of lung cancer and precision benefit of smoking cessation is a promising but untested strategy to promote health behavior changes to reduce cancer risk. To address this gap, polygenic risk scores (PRSs) emerge as a valuable approach to assess disease susceptibility among populations and pinpoint individuals at higher risk[2–4]. PRSs can be derived from large-scale genome-wide association studies (GWAS) to estimate individual disease risk and have shown promise in predicting health outcomes and promoting preventive healthcare[5–9]. Despite their potential, PRSs' implementation in primary care is limited, especially in diverse populations. Implementing a PRS-based precision intervention is crucial in order to address the multifaceted needs of different communities and individuals[10]. Harnessing PRSs effectively can make significant progress in mitigating lung cancer's public health impact.

Ongoing studies like eMERGE[11], GenoVA[12], and WISDOM[13] are leading the implementation of PRS into genetic risk reports (**Table 1**). They aim to personalize medical reports and understand the impact of PRS on screening, diagnostic procedures, and patient behavior. Notably, a gap persists as these initiatives have not yet formulated a PRS specifically for lung cancer. A likely reason is that the global burden of lung cancer is primarily driven by tobacco smoking rather than genetics[14,15]. However, accounting for the genetic basis of lung cancer may provide patients and clinicians with additional actionable information. The unique value proposition of a lung cancer-specific PRS lies in leveraging established and clear guideline-based prevention strategies, including smoking cessation treatment and lung cancer screening[16]. By incorporating PRSs for lung cancer and difficulty quitting smoking without treatment, there is an opportunity to revitalize and enhance these often-under-utilized prevention practices.

We introduce the Genomic Informed Care for Motivating High Risk Individuals Eligible

for Evidence-based Prevention (GREAT) framework as a novel approach to incorporate

PRS-enabled interventions in clinical settings (**Figure 1**). The core of GREAT is the use

of PRSs that offer precise risk estimates for lung cancer and difficulty quitting smoking.

By providing patients with personalized risk information, we aim to activate behavior

change mechanisms that promote preventive actions. The primary targets of this

intervention are high-risk individuals eligible for evidence-based prevention practices,

such as lung cancer screening and smoking cessation. By integrating precision risk

information with the benefits of timely interventions, GREAT empowers patients to make

informed decisions about their health and motivates them to take proactive steps

towards prevention. The personalized information may increase the patient uptake of

evidence-based treatment by activating potential mechanisms such as treatment.

Guided by enhanced outcome expectancy and self-efficacy based on the Capability-

Opportunity-Motivation-Behavior (COM-B) model and Theoretical Domains Framework

(TDF)[17–19]. Ultimately, our objective is not only to motivate, but to significantly reduce

lung cancer morbidity and mortality through this innovative care paradigm.

Effectively translating PRSs into clinical practice requires a comprehensive and

pragmatic translational roadmap for equitable and effective implementation (**Figure 1**).

First, to address ancestry diversity, we take a two-step approach of (1) constructing

PRS based on large-scale multi-ancestry GWAS, and (2) standardizing PRS

distributions across the continuum of genetic ancestry to ensure accurate risk

stratification based on PRS distributions for all patients[20]. Second, to document

accuracy and transportability of the PRSs to diverse populations, we perform large-

scale validation using diverse data from the Genetic Informed Smoking Cessation

(GISC) trial[21], UK Biobank (UKBB)[22], and All of Us Research program (AoU)[23]. Third,

we translate risk into actionable categories by setting appropriate thresholds for the

PRS. The alignment of these thresholds with clinical significance involves many

considerations for meaningful risk stratification. Fourth, we propose clear and patient-

friendly communication strategies, including visual aids and educational materials, to

facilitate understanding and meaningful interactions between patients and healthcare

providers. Effectively communicating both the risk and precision of the PRS results is
challenging but essential to empower patients to make informed decisions about their
health. Moreover, it is crucial to consider patient perceived risk, perceived benefit, and
personal relevance when discussing PRS results with patients. Patients' understanding
and interpretation of PRS may vary, leading to differing levels of engagement in
preventive actions. Hence, comprehensive patient education programs can enhance
awareness and knowledge about PRS, its implications, and available preventive
measures.
132
In this paper, we introduce the design for two cluster randomized clinical trials (RCT): (1)
PRECISE, which evaluates the effectiveness of a multilevel intervention, *RiskProfile*, on
increasing lung cancer screening and tobacco treatment utilization in primary care
(NIDA Grant 5R01CA268030-02); and (2) MOTIVATE, which evaluates the effect of
PrecisionTx, a multilevel intervention to promote precision tobacco treatment in primary
care (NIDA Grant 5R01DA056050-02). Through the innovative use of PRS, our aim is to
motivate lung cancer screening and tobacco treatment among high-risk patients. We
present a new care paradigm (**Figure 1**) and outline a translational roadmap (**Figure 2**)
that discusses potential barriers and solutions for implementation. By incorporating
personalized risk assessments, such PRS-enabled interventions have the potential to
significantly improve lung cancer prevention strategies and patient outcomes.
144
Materials and Methods
<u>1000 Genomes Project Phase 3 reference data and principal components analysis</u>
We use the 1000 Genomes Project Phase 3 (1000G)[24,25] as a reference for genetic
ancestry inference, as it is publicly accessible and includes genotype data from diverse
populations. The 1000G dataset includes 3,202 individuals, with 633 Europeans (EUR),
893 Africans (AFR), 585 East Asians (EAS), 601 South Asians (SAS), and 490 Admixed
Americans (AMR). We conducted principal components analysis (PCA) plink 2.0[26] on all
3,202 samples, using 55,248 SNPs that are shared among the recommended SNPs set
by gnomAD[27], 1000G reference data, UKBB and GISC validation data, and the

23andMe genotyping array used for the trial (**Figure 3, Supplementary Figure 1,**

Supplementary Table 4).

We ran a random forest classifier to map each individual in 1000G to their respective

populations using the first 5 PC scores. We then projected our validation data to this PC

space and applied the same random forest classifier to produce "genetically-inferred"

ancestry labels. Individuals with a predicted probability less than 90% for any of the five

ancestries were labeled as "Other." While our proposed framework removes the need

for labels in the clinic, we use them here for illustrative purposes in validation.

<u>Validation in GISC, UK Biobank, and All of Us</u>

We validated our PRS approaches in three datasets: Genetically Informed Smoking

Cessation Trial (GISC)[21], UK Biobank (UKBB)[22], and All of Us Research Program

(AoU)[23] Here we present are brief background of the three studies. More details of the

study background are provided in the **Supplementary Note**, and sample characteristics

regarding sex, age, and outcomes information in UKBB and AoU are provided in

Supplementary Table 1.

<u>GISC Trial:</u> The GISC trial, conducted at conducted at Washington University in St

Louis[21], included 822 current or previous smokers. Genetic data were available for 796

individuals (503 European, 257 African, 36 Other self-reported ethnicities), This dataset

was primarily used for ancestry inference validation due to its relevance to our

PRECISE and MOTIVATE trials.

<u>UKBB:</u> The UKBB dataset included 340,154 unrelated individuals with rich genetic and

clinical data. This cohort consisted of 6,844 African, 730 Admixed American, 770 East

Asian, 313,279 European, 7,197 South Asian, and 11,334 Other individuals by

genetically-inference ancestry. The lung cancer analysis included 1,830 cases (ICD10

codes C34.0-C34.9) and 338,334 controls. The smoking cessation analysis involved

152,406 ever-smokers (117,483 former and 34,923 current), excluding 186,040 never

smokers and 1,312 prefer-not-to-answer responses.

<u>AoU</u>: The AoU dataset included 210,826 unrelated individuals with whole-genome

sequencing data. This cohort comprised 45,108 African, 32,563 Admixed American,

3,873 East Asian, 110,712 European, 1,689 South Asian, and 16,881 Other individuals

by genetically-inference ancestry. We focused on 152,916 current or previous smokers

for our smoking analysis.

<u>Construction of polygenic risk scores</u>

Our trial incorporates the latest findings by utilizing recently genome-wide association

study (GWAS) summary statistics for lung cancer[28] and difficulty quitting smoking[29],

excluding UK Biobank samples to avoid overlapping with our validation data. While

these meta-analyses predominantly consist of individuals of European ancestry, they

also include a substantial proportion of non-European ancestry — about 26% for lung

cancer and 21% for difficulty quitting smoking — which enhances the generalizability of

the findings[30,31].

For lung cancer risk, we started with 128 published SNPs found to be predictive of 5-

year and lifetime cumulative risk for lung cancer[16]. Out of these, 101 SNPs overlapped

with the published summary statistics, reference, and validation data (1000G, UKBB,

GISC and AoU), and the 23andMe genotyping array used for the trial (**Supplementary**

Figure 1). These SNPs were assigned effect sizes from the fixed-effect meta-analyses

estimates in the latest lung cancer GWAS that includes EUR, AFR, and EAS ancestry[28].

For difficulty quitting smoking, we identified 175 SNPs predictive for smoking cessation

following the same filtering procedure for lung cancer[29].

The PRS construction began with the alignment of genotype data to the summary

statistics, ensuring consistent PRS regardless of allele coding. Specifically, for any SNP

G with reversed alleles, we recoded it as $2 - G$ to avoid discrepancies. The raw PRS for

an individual i with M SNPs was computed as

$$PRS_i = \beta_1 G_{i1} + \beta_2 G_{i2} + \cdots + \beta_M G_{iM}.$$

PRS calculations were performed using R, with genotype data input via the genio

package[32]. PRS SNPs and weights for lung cancer and difficulty quitting smoking are

provided in **Supplementary Tables 2-3**, respectively.

<u>Standardizing PRS distributions across the continuum of genetic ancestry</u>

We standardized the PRS distributions for lung cancer and difficulty quitting smoking

using the 1000G dataset, employing a regression-based method to adjust for

distributional differences across ancestries (**Supplementary Tables 4-5**)[20]. This

adjustment process involves two key steps:

1. <u>Mean adjustment</u>: we conducted a linear regression of the raw PRS against the top

five PCs derived from the PCA:

$$PRS_i = \alpha_0 + \alpha_1 PC_{i1} + \alpha_2 PC_{i2} + \cdots + \alpha_5 PC_{i5} + \epsilon_i^{mean}.$$

226   We then computed residuals r_i of the raw PRS that account for mean differences in

227   PRS distributions across ancestry:

$$r_i = PRS_i - \widehat{\alpha_0} - \widehat{\alpha_1} PC_{i1} - \cdots - \widehat{\alpha_5} PC_{i5}.$$

228   2. <u>Variance adjustment</u>: using the square residuals r_i^2 as a proxy for PRS variance, we

229   ran a secondary linear regression:

$$r_i^2 = \gamma_0 + \gamma_1 PC_{i1} + \gamma_2 PC_{i2} + \cdots + \gamma_5 PC_{i5} + \epsilon_i^{var}.$$

232   The final ancestry-adjusted PRS for each individual i was then computed as:

$$PRS_i^{adj} = \frac{PRS_i - \widehat{\alpha_0} - \widehat{\alpha_1} PC_{i1} - \cdots - \widehat{\alpha_5} PC_{i5}}{\sqrt{\widehat{\gamma_0} + \widehat{\gamma_1} PC_{i1} + \widehat{\gamma_2} PC_{i2} + \cdots + \widehat{\gamma_5} PC_{i5}}}$$

This standardization resulted in a PRS distribution with mean 0 and variance 1 across

ancestries, ensuring that genetic risk is accurately reflected independent of ancestry.

This method is crucial for individuals with admixed or unknown ancestry, where discrete

ancestry-specific models are inappropriate[33,34].

<u>Definition of patient risk categories</u>

We stratified patients by genetic risk for lung cancer and difficulty quitting smoking by

calculating odds ratios (ORs). ORs compare the probability of an outcome occurring in

individuals within a percentile range p (i.e. 80-100%) of the ancestry-adjusted PRS

distribution to those within a lower percentile range q (i.e. 0-20%).

$$OR_{pq} = \frac{P(Y = 1|PRS \in p)/P(Y = 0|PRS \in p)}{P(Y = 1|PRS \in q)/P(Y = 0|PRS \in q)}$$

We established cut points in the PRS distribution to categorize individuals into three risk

groups: "at risk", "high risk", and "very high risk". For lung cancer, we defined these

categories as the bottom 20%, middle 60%, and top 20% of the PRS distribution. For

difficulty quitting smoking, categories were the bottom, middle, and top 33%. These

thresholds were chosen to communicate personalized risks and benefits to high-risk

patients in our trials, all of whom are eligible for lung cancer screening due to heavy

smoking. Since difficulty quitting smoking lacks established absolute risk rates, we used

these percentiles to provide a more agnostic risk assessment.

We use the distribution of our ancestry-adjusted PRSs among all 1000G samples to set

percentile ranges and evaluate corresponding odds ratios among UKBB and AoU

participants. For comparison, we also evaluate odds ratios using ancestry-matched raw

PRS distributions, i.e. European-only 1000G PRS distribution for UKBB and AoU

participants with genetically predicted European ancestry. For individual with "Other"

predicted ancestry, we use the overall raw PRS distribution among all 1000G samples.

Results

Harmonization PRS distributions across ancestry

We found notable variation in raw PRS distributions across ancestries, highlighting that

applying a universal cutoff for raw PRS without accounting for ancestry can lead to

biased risk profiling and inaccurate clinical recommendations (**Figure 4**). However, our

regression-based ancestry adjustment across all three datasets yields much more

standardized distributions across ancestries. Specifically, the adjusted proportions of

individuals within each risk category closely align with 20%-60%-20% for lung cancer,

and 33.3%-33.3%-33.3% for difficulty quitting smoking. This adjustment ensures that

patients of any background can be compared against a unified reference distribution for

each outcome (**Supplementary Tables 6a-f**). This standardization places individuals

across all ancestries on the same scale, allowing for a single risk stratification cutoff

regardless of ancestral background. Such measures importantly enable fair risk

assessment for individuals who may be labelled as "Other", who may not fit well into a

binned ancestry-specific risk model.

<u>Risk stratification for lung cancer and smoking cessation in UK Biobank and All of Us</u>

After assigning UKB and AoU participants as "at risk", "high risk", or "very high risk" for

lung cancer and difficulty quitting smoking, we identified significant odds ratios for both

traits across different ancestry groups (**Figure 5**, **Supplementary Tables 7-10**). Our

ancestry-adjusted PRS yielded similar ORs as using ancestry-matched distributions,

demonstrating that a single PRS distribution can be appropriately applied to all

individuals. In UKBB, the overall ORs for lung cancer 1.42 (95% CI: 1.24 – 1.65) for the

"high risk" group and 1.85 (95% CI: 1.58 – 2.18) for "very high risk" group compared to

the "at risk" group (**Supplementary Table 7a**). In AoU, these ORs were slightly higher –

1.65 (95% CI: 1.36 – 2.02) for "high risk" group and 2.39 (95% CI: 1.93 – 2.97) for "very

high risk" group. While the ORs in non-European ancestries within UKBB were not

significant, they were significant and even higher than those for European ancestries in

AoU (**Supplementary Table 8a**). Moreover, the ORs for "Other" ancestry group in AoU

were much higher and more significant using the ancestry-adjusted PRS compared to

raw PRS, where an ancestry-matched risk distribution is least suitable (**Supplementary**

Table 8b).

We observed similar patterns for difficulty quitting smoking, where the ancestry-adjusted

PRS performed similar or better than using ancestry-matched distributions for raw PRS.

In UKBB, the overall ORs for difficulty quitting smoking were 1.19 (95% CI: 1.15 – 1.22)

for "high risk" group and 1.36 (95% CI: 1.32 – 1.41) for "very high risk" group

(**Supplementary Table 9a)**. In AoU, the ORs were 1.12 (95% CI: 1.08 – 1.15) for "high

risk" group and 1.32 (95% CI: 1.28 – 1.36) for "very high risk" (**Supplementary Table**

10a) group. Notably, we observed higher and more significant ORs in non-European

AoU participants when using the ancestry-adjusted PRS compared to the raw PRS.

Although the improvement within each specific ancestry group was not as substantial,

the aggregate ORs in all non-European groups increased from 0.89 (95% CI: 0.86 –

0.93) to 1.05 (95% CI: 1.01 – 1.09) in the "high risk" group, and from 1.07 (95% CI: 1.03

– 1.11) to 1.23 (95% CI: 1.18 – 1.28) in the "very high risk" group.

Using ancestry-adjusted PRS ensures accurate risk stratification across all ethnic

backgrounds, a critical consideration given the substantial variability in raw PRS

distributions across diverse populations. The outcome-based validation in UKBB and

AoU further verifies that the ancestry-adjusted PRS provides valid risk stratification, and

often yields better risk stratification for non-European ancestries compared to ancestry-

matched modeling. These findings collectively facilitate a more robust and standardized

application of PRS in clinical reporting.

<u>Translating polygenic risk scores into clinical reports</u>

We highlight two example trials: PRECISE (NIDA Grant 5R01CA268030-02) and

MOTIVATE (NIDA Grant 5R01DA056050-02), designed to promote health behavior

change using genetically-informed interventions, RiskProfile and PrecisionTx,

respectively. These interventions incorporate PRS to communicate precision risk of lung

cancer and precision benefits of smoking cessation, promoting evidence-based

practices such as cancer screening and tobacco treatment in high-risk individuals who

smoke and/or are eligible for lung cancer screening. PRS risk stratification from either

RiskProfile or PrecisionTx, along with clinical information, is delivered within a

comprehensive report that includes actionable recommendations to reduce lifetime risk

(**Figure 6** and **Figure 7**). Access to 23andMe genotypes and expanded health

information has been a motivating component for the research participants. Both

PRECISE and MOTIVATE are currently in the preliminary phases of recruiting primary

care providers and patients. The recruitment strategy aims to engage over 100

physicians and 1600 patients in these trials.

Discussion

In this study, we introduce the GREAT framework in primary care, applying PRSs in two

trials to provide precise risk estimates for lung cancer and difficulty quitting smoking to

high-risk individuals. These estimates aim to activate behavior change mechanisms that

promote health. To enable the interventions, we present a translational roadmap to

implement genetic data in PRS-enabled interventions designed to promote health

behaviors, evaluating their effectiveness in motivating high-risk patients to increase

cancer screening and smoking cessation.

Importantly, we have accomplished our goals of generating behavior-change

interventions by a) framing our translational message specifically for high-risk patients

who have not received guideline-recommended cancer screening or tobacco

treatment[35–38], b) translating risk categories into precision risk and benefit that are

designed to motivate health behavior changes, and c) ensuring inclusion of diverse

ancestry with PC-regression-based PRS adjustment.

Our goal is to enable a robust implementation of PRS in currently funded clinical trials to

evaluate the efficacy of these relatively novel interventions. The GREAT framework

guides the implementation of PRS-enabled interventions in primary care. Future

research need to address critical questions such as timing, methodology, and location of

these interventions' delivery to patients and providers to optimize its acceptability,

understanding, and impact.

Our approach to ancestry adjustment of PRS employs widely accessible data from the

1000G dataset, as an alternative to methods in the GenoVA[12] and eMERGE[11] studies

that use data from the Mass-General Brigham Biobank and AoU, respectively. We

validated the transferability of our 1000G-based standardization in external datasets

from the UKBB, GISC and AoU, allowing future trials to adopt a similar methodology

irrespective of their specific genetic data. By utilizing our provided PC loadings and PRS

standardization formula for lung cancer and difficulty quitting smoking, new patients in

these trials can receive accurate risk categorization reports, bypassing the inaccuracies

of self-reported ethnicity and the need for re-training PCA models.

A notable gap in current practice is the absence of genetic information in electronic

health records (EHRs) for decision support and the lack of PRS generation in clinical

labs. Implementing precision interventions in primary care necessitates a workflow that

incorporates EHRs for recruitment, biomarker testing protocols, and standardized

processes to generate personalized intervention reports[39]. This requires collaborations

with primary care stakeholders, community advisory boards, genetic counseling, and

health communication to improve intervention clarity, accuracy, and impact[40–44]. Patients

expressed a notable interest in receiving personalized interventions. In our previous

study, 85% of smoking patients reported a high interest in receiving genetically tailored

tobacco treatment[45]. Further, a substantial majority (95%) of individuals who smoke

endorsed the importance of receiving genetic results to guide their treatment[41].

Following receipt of a personalized genetic risk profile for smoking cessation, 91% of

participants who smoke found the tool highly useful for understanding their health, cope

with health risks, and feeling more in control of their health[42]. Such pronounced interest

and the perceived significance of genetic data highlight the growing demand for

personalized interventions among patients who smoke. Personalized interventions may

increase patient compliance. For example, study found that patients reported higher

interest in taking medication (97.5% vs. 61.0%, p<.0001) when medication was

personalized based on their genetics[45]. However, substantial evidence suggests the

complex interplay of fear, fatalism, and risk perception when patients face lung cancer

screening[46–49] Therefore, it is important to evaluate the translation potential of

personalized genetics in motivating patients for positive behavior change.

Unlike most current research that evaluates PRS-enabled interventions in general

patient populations, our work uniquely focuses on designing and evaluating these

interventions specifically among high-risk patients who will benefit tremendously from

recommended health behaviors such as lung cancer screening and smoking cessation,

when general medical advice is not enough to motivate such behaviors.

Here we share three key design considerations for best practices. First, for equitable

implementation of precision health interventions, tools must be designed with active

engagement from racial/ethnic minority communities, rather than solely examining their

effectiveness for these communities post hoc. We engage in ongoing participatory

sessions with racial and ethnic minority communities and advisory boards across all

phases through iterative cycles of intervention development, feedback, and testing so

that innovative genomics-informed tools are beneficial across diverse populations.

Second, we have chosen <u>clinically meaningful thresholding</u> for PRS risk categories in

communicating personalized risks and benefits to patients. These categories were

selected because all participants in our ongoing trials are high-risk primary care patients

eligible for lung cancer screening, who are current or former heavy smokers. We

defined lung cancer risk by the bottom 20%, middle 60% and top 20%, and difficulty

quitting smoking by slightly more agnostic tertiles, to motivate positive behavior change.

We aim to follow best practices of communicating uncertainties and deciding between a

continuous or categorical risk presentation. Transparency about the imprecision in both

risk estimates and action thresholds for PRS is essential.

Third, we plan to <u>update our workflow</u> to adapt to new GWAS findings and evolving

methodologies. As scientific knowledge advances, outdated PRS predictions can hinder

effective implementation. A dynamic PRS framework that allows for regular updates

based on new discoveries is essential. This ensures that PRS-based interventions

remain current and aligned with the latest advancements, reducing the implementation

gap and maximizing their impact on preventive healthcare outcomes. Following current

genetic counseling recommendations, we have established a process to incorporate

new evidence into our intervention for smoking cessation and lung cancer risk. This

process will adjudicating new population-specific evidence on genetics and biomarkers,

evaluating its impact on personal and population-level risk changes, and effectively

communicating the dynamic nature of genetic evidence to patients and providers.

Our work have several limitations, but we hope contribute to the knowledge pool for the

best practices in creating PRS-enabled interventions that may be disease-, population-,

or context-specific. Our approach is tailored for our unique outcomes (lung cancer and

difficulty quitting smoking), population (patients eligible for lung cancer screening and

tobacco treatment), and context (primary care) to optimize health impact. A notable

limitation is the underrepresentation of non-European populations in the multi-ancestry

GWAS employed to derive the PRS weights. This underrepresentation may reduce the

predictive power of the PRS in non-European populations. The dominance of European

populations persists in existing GWAS[50–53], not limited to lung cancer and smoking

cessation. However, with the burgeoning emphasis on incorporating minority

populations in GWAS analyses and the development of new PRS approaches and

toolkits to enhance predictive power in diverse populations [7–9,34,54–56], we can iteratively

refine PRS implementation in our trial to synchronize with the latest advancements.

Many questions remain for the near future. First, how can we reduce the time lag from

evidence to implementation? The constant evolution of evidence identifying new

biomarkers for treatment is a challenge. For instance, our recent work highlights the

potential of PRSs in guiding future treatment approaches[57]. Despite actionable precision

treatment findings, the ever-changing evidence base and the perception of better data

have hindered effective implementation[43,58]. To address this, we aim to use cutting-edge

metabolic and genetic markers that offer robust evidence for precision treatment,

reducing the time from evidence generation to practical application. This approach

allows us to measure and report the time from landmark publications to the

implementation of key findings [59], enhancing the efficiency and effectiveness of

precision treatment and ensuring patients benefit from the latest recommendations.

Second, can we truly evaluate the effect of precision interventions? We expect that

precision interventions may activate multiple mechanistic pathways to the uptake and

efficacy of lung cancer screening or tobacco treatment. Understanding these

mechanisms is essential to refine for intended outcomes and contexts. Third, can these

precision interventions be scaled in the real-world clinics? Evidence shows that

physicians are highly receptive to medication recommendations based on biomarkers[60].

To reduce burden, we need to leverage existing EHR tools (e.g. Best Practice

Advisories) and training to efficiently facilitate physician prescribing[61,62]. Understanding

of mechanistic and implementation outcomes will guide scalable, efficient delivery

components for integration into clinic workflows[39], using trained embedded staff, and

digital therapeutic tools to enable these PRS-informed behavioral interventions[63].

In conclusion, a <u>well-designed roadmap that validates the PRS, incorporates multi-</u>

<u>ancestry GWAS-based weights, translates risk into actionable categories,</u>

<u>communicates effectively, considers patient perspectives, and accommodates evolving</u>

<u>science</u> is essential for the equitable and pragmatic translation of PRS into clinical care.

By addressing the barriers and implementing potential solutions at each stage, we can

leverage PRS to improve preventive healthcare and significantly reduce the burden of

lung cancer.

Acknowledgements

We would like to thank Reeya Joseph for her editorial support with the introduction, Peter Kraft for his advice on our manuscript, and Scott Vrieze for his assistance with summary statistics for difficulty quitting smoking. We would also like to thank and acknowledge the participants enrolled in the UK Biobank (obtained under UK Biobank resource application 52008) and GISC trial for contributing vital data to this work.

This research was supported by NIH Training Grant T32GM135117 and NSF Graduate Research Fellowship DGE-2140743 (T.C.), R35-3CA197449, R01-HL163560, U01-HG009088, and U01-HG012064 (X.L.), NIH Intramural Research Program (H.Z.), NIH 5T32-HL007776-25, R01-DA056050, R01-CA268030, P30-CA091842-19S5, P30-CA091842-16S2 and P50-CA244431 (L.C.) and U19-CA203654.

Author Contributions

T.C., H.Z., and L.C. conceived the project, T.C., G.P., and L.F. carried out all data analyses under the supervision of H.Z. and L.C. G.S. and D.J. assisted with obtaining and processing GWAS summary statistics for difficulty quitting smoking. T.C., G.P., H.Z., and L.C. drafted the manuscript. All co-authors reviewed and approved the final version of the manuscript.

Conflicts of Interest

Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371, "Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Michael J. Bray is an employee at ThinkGenetic, Inc. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. All other authors have no conflict of interests to report.

Data and Code Availability

R code and plink commands, as well as accompanying data, used for analysis are provided in a walkthrough available on GitHub at https://github.com/chen-tony/GREAT.

Genotype data from the 1000 Genomes Project (Phase 3) were acquired via the plink website https://www.cog-genomics.org/plink/2.0/resources. Population information were obtained from public resources: ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/ and https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000G_2504_high_coverage/1000G_698_related_high_coverage.sequence.index.

506   **Figures**

Mechanisms for health behavior change

Figure 1. Care Paradigm: Genomic Informed Care for Motivating High Risk
Individuals Eligible for Evidence-based Prevention (GREAT). The GREAT
framework is a primary care paradigm that integrates genetic and clinical risk in
precision health. Individuals and their providers in two upcoming trials (PRECISE and
MOTIVATE) are enrolled and provided with multilevel interventions (e.g. RiskProfile and
PrecisionTx) to promote clinical outcomes of lung cancer screening, tobacco treatment,
and successful smoking cessation in primary care settings. Mechanisms of health
behavior changes (e.g., perceived benefit, self-efficacy, and outcome expectancy) will
be evaluated. During the specific actionable recommendations phase, personalized
shared decision-making will be facilitated by multilevel actions between patients and
clinicians for better clinical outcomes.

Figure 2 Roadmap for translating genetic data to a genetic risk profile as a multilevel intervention in primary care. In step 1, enrolled participants' genetic data are analyzed by 23andMe's Clinical Laboratory Improvement Amendments (CLIA) certified genotyping process. Imputation and quality controls are conducted through the Trans-Omics for Precision Medicine (TOPMed) server to ensure the integrity and reliability of the genetic data, as well as to impute the GWAS variants. Step 2 involves identifying available GWAS variants and weights to create the raw Polygenic Risk Scores (PRS). The PRS is adjusted for genetic ancestry using reference data such as the 1000 Genomes Project Phase 3 and applied to validation data such as the UK Biobank to establish risk categories and compute ORs. In step 3, these scores are converted into 3 risk levels based on the established thresholds. In step 4, a report with precision treatment is created and communicated to both the participant and the provider to make informed and educated decisions. Behavioral interventionists (research staff who are trained, certified, and supervised by a team of genetic counselor, psychologist, and psychiatrist) offer personalized guidance on behavior change, leveraging the updated genetic insights. The outcome aims to increase lung cancer screening orders, improve participant adherence, promote smoking cessation, and highlight the benefits of tobacco treatment.

Figure 3. Cross-dataset distribution of genetic ancestry via PCA Projections in 1000G, GISC, UKBB, and AoU. This figure illustrates the utility of principal components analysis (PCA) loadings obtained from the 1000 Genomes Project Phase 3 (1000G) in discriminating ancestries within external datasets, the Genetically Informed Smoking Cessation (GISC) trial. PCA was initially conducted on the globally diverse genotype data of 1000G. The resultant PCA-space was then used to project genotype data from GISC, UKBB, and AoU. The scatter plot displays the first and second PCs for each

548   individual in these datasets, with points distinctly marked by genetically-inferred
549   ancestry.

Figure 4 Ancestry adjustment of PRS for lung cancer and quit difficulty PRS across ancestral populations. We showcase the adjustment process for polygenic risk scores (PRS) for lung cancer (Panel A) and difficulty quitting smoking (Panel B) within the 1000 Genomes Project (1000G), GISC Trial, UK Biobank, and All of Us datasets. It displays both raw and ancestry-adjusted PRS, with data points color-coded according to genetically-inferred ancestries. EAS, AMR, and SAS ancestries were removed for GISC due to their small sample sizes. Ancestry adjustment effectively centers the PRS for different ancestries, mitigating the risk of incorrect stratification due to ancestry-related biases. Dotted vertical lines correspond to the 20th and 80th percentiles for lung cancer PRS distribution and 33rd and 67th percentiles for difficulty quitting smoking PRS among all 3,202 samples in the 1000 Genomes Project.

Figure 5. Risk stratification for lung cancer and difficulty quitting smoking using raw and ancestry-adjusted PRS. This figure illustrates the odds ratios (ORs) with associated 95% confidence intervals of PRSs for lung cancer (A) and difficulty quitting smoking (B) among UK Biobank (N=340,154 for lung cancer and N=152,406 for smoking), and All of Us (N=210,826 for lung cancer and N=152,916 for smoking) participants. We compare risk stratification using a raw PRS with ancestry-matched percentiles, and our ancestry-adjusted PRS with the same percentiles for all individuals.

Figure 6. Example 1 clinical report: RiskProfile. We present example 1 for genomically-informed interventions using the GREAT framework. RiskProfile is designed to motivate lung cancer screening and tobacco treatment among screening-eligible patients. This intervention utilizes ancestry-adjusted PRS to stratify patients into "at risk" (yellow), "high risk" (orange), and "very high risk" (red) genetic risk categories. RiskProfile focuses on prevention and expands beyond personalized risk to also provide personalized benefit of cancer screening and use a multilevel intervention design directed to both physicians and patients in clinical settings. In an ongoing NCI-funded trial (NCT05627674), the effect of RiskProfile on clinician ordering and patient completion of lung cancer screening will be evaluated.

582
Figure 7. Example 2 clinical report: PrecisionTx. We present example 2 for
genomically-informed interventions using the GREAT framework. PrecisionTx is
designed to motivate tobacco treatment among patients who smoke. This intervention
utilizes ancestry-adjusted PRS to stratify patients into "at risk" (yellow), "high risk"
(orange), and "very high risk" (red) genetic risk categories. PrecisionTx focuses on
treatment and expands beyond personalized risk to also provide personalized benefit of
tobacco treatment, and use a multilevel intervention design directed to both physicians
and patients in clinical settings. In an ongoing NIDA-funded trial (NCT05846841), the
effect of PrecisionTx on clinician ordering, patient adherence, and smoking abstinence
will be evaluated.

Tables

	GenoVA	eMERGE	Wisdom	PRECISE / MOTIVATE
Goal	Motivate early diagnosis	Increasing clinical actions to mitigate risk of future disease	Personalized screening frequency	Motivate lung cancer screening (LCS) / tobacco treatment
Targets				
Target population	All general Veterans' Affairs PCP* and patients	Patients in the large healthcare system	All women can sign up online	**High risk** PC patients (LCS eligible / smokers) and their PCPs
Condition(s)**	BrCa, PrCa, CRCa, Afib, CAD, T2D	BrCa, PrCa, CRCa, Afib, CAD, T1D, T2D, BMI, Asthma, CKD, HCL	BrCA	**LC, smoking cessation**
Target outcome	New diagnoses	Change screening practice or lifestyle	Screening compliance and cancer detection	**LCS, tobacco tx, and smoking cessation**
Polygenic Risk Scores				
Genotyping	Study team		Color genomics	23andMe
Imputation	1000 Genomes	All of Us		TOPMed
Create PRS	Top or many variants European weights Ancestry calibration	Terra cloud platform Ancestry calibration	Color genomics	Top independent variants Multi-ancestry weights Ancestry calibration
Risk Stratification	2 levels (OR of 2)	OR of 5-10		3 levels (top 20%, middle, bottom 20%) or tertiles
Intervention Design				
Risk representation	Only genetic Format of relative risk	Combined clinical + genetic Format of absolute risk	Combined clinical + genetic Format of absolute risk	Separate genetic + clinical Format of relative risk
Messaging	Average vs. elevated risk	Average vs. elevated risk	No discussion of risk Only recommend screening schedule	At risk, at high risk, or at very high risk
Behavior mechanisms targeted				**Perceived risk/benefit, Self efficacy, Personal relevance**

* PCP=primary care provider

** BrCa=breast cancer, PrCa=prostate cancer, CRCa=colorectal cancer, Afib=atrial fibrillation, CAD=coronary artery/heart disease, T2D=type 2 diabetes, T1D=type 1 diabetes, BMI=body mass index/obesity, CKD=chronic kidney disease, HCL=hypercholesterolemia, lung cancer=lung cancer

Table 1. **Research on PRS use in clinical trials**. We compare the PRECISE and MOTIVATE trials, part of our GREAT framework, with existing PRS-informed trials: GenoVA, eMERGE, and WISDOM. Bolded text in the PRECISE / MOTIVATE column highlight the points where our trials differ from the current trials. Namely, the PRECISE and MOTIVATE trials investigate lung cancer and smoking and will focus on <u>high risk</u> patients who are smokers or eligible for lung cancer screening. We also look at lung cancer screening, tobacco treatment, and smoking cessation as unique target outcomes. Finally, in addition to genetic and clinical risk messaging, the two trials have a unique emphasis on behavior mechanisms around lung cancer and smoking.

References

612   1.   Kocarnik, J. M. *et al.* Cancer Incidence, Mortality, Years of Life Lost, Years Lived With
613   Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019.
614   *JAMA Oncol* **8**, 420 (2022).

615   2.   Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic
616   risk scores. *Nature Reviews Genetics* vol. 19 581–590 Preprint at
617   https://doi.org/10.1038/s41576-018-0018-x (2018).

618   3.   Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to clinical instruments.
619   *Genome Medicine* vol. 12 Preprint at https://doi.org/10.1186/s13073-020-00742-5
620   (2020).

621   4.   Adeyemo, A. *et al.* Responsible use of polygenic risk scores in the clinic: potential benefits,
622   risks and gaps. *Nature Medicine* vol. 27 1876–1884 Preprint at
623   https://doi.org/10.1038/s41591-021-01549-6 (2021).

624   5.   Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic
625   Risk Scores. *Am J Hum Genet* **97**, 576–592 (2015).

626   6.   Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk to
627   disease from genome-wide association studies. *Genome Res* **17**, 1520–1528 (2007).

628   7.   Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
629   performance across diverse populations. *Nat Genet* (2023) doi:10.1038/s41588-023-
630   01501-z.

631   8.   Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat
632   Genet* **54**, 573–580 (2022).

633   9.   Chen, T., Zhang, H., Mazumder, R. & Lin, X. Ensembled best subset selection using
634   summary statistics for polygenic risk prediction. *bioRxiv* (2023)
635   doi:10.1101/2023.09.25.559307.

636   10.   Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
637   disparities. *Nat Genet* **51**, 584–591 (2019).

638   11.   Linder, J. E. *et al.* Returning integrated genomic risk and clinical recommendations: The
639   eMERGE study. *Genetics in Medicine* **25**, 100006 (2023).

640   12.   Hao, L. *et al.* Development of a clinical polygenic risk score assay and reporting workflow.
641   *Nat Med* **28**, 1006–1013 (2022).

642   13.   Shieh, Y. *et al.* Breast Cancer Screening in the Precision Medicine Era: Risk-Based
643   Screening in a Population-Based Trial. *J Natl Cancer Inst* **109**, djw290 (2017).

644   14.   Zhang, P. *et al.* Association of smoking and polygenic risk with the incidence of lung
645   cancer: a prospective cohort study. *Br J Cancer* **126**, 1637–1646 (2022).

646   15.   Kanwal, M., Ding, X.-J. & Cao, Y. Familial risk for lung cancer. *Oncol Lett* **13**, 535–542
647   (2017).

648   16.   Hung, R. J. *et al.* Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk
649   Model. *Cancer Res* **81**, 1607–1615 (2021).

650   17.   Michie, S. Making psychological theory useful for implementing evidence based practice:
651   a consensus approach. *Qual Saf Health Care* **14**, 26–33 (2005).

652   18.   Cane, J., O'Connor, D. & Michie, S. Validation of the theoretical domains framework for
653   use in behaviour change and implementation research. *Implementation Science* **7**, 37
654   (2012).

655   19.   Atkins, L. *et al.* A guide to using the Theoretical Domains Framework of behaviour change
656   to investigate implementation problems. *Implementation Science* **12**, 77 (2017).

657   20.   Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk score for type 2
658   diabetes in diverse populations. *Genome Med* **14**, 70 (2022).

659   21.   Chen, L. *et al.* Genetic Variant in *CHRNA5* and Response to Varenicline and Combination
660   Nicotine Replacement in a Randomized Placebo-Controlled Trial. *Clin Pharmacol Ther* **108**,
661   1315–1325 (2020).

662   22.   Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a
663   Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med* **12**, e1001779 (2015).

664   23.   Bick, A. G. *et al.* Genomic data in the All of Us Research Program. *Nature* (2024)
665   doi:10.1038/s41586-023-06957-x.

666   24.   Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).

667   25.   Byrska-Bishop, M. *et al.* High-coverage whole-genome sequencing of the expanded 1000
668   Genomes Project cohort including 602 trios. *Cell* **185**, 3426-3440.e19 (2022).

669   26.   Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
670   datasets. *Gigascience* **4**, 7 (2015).

671   27.   Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation in
672   76,156 human genomes. *bioRxiv* 2022.03.20.485034 (2022)
673   doi:10.1101/2022.03.20.485034.

674   28.   Byun, J. *et al.* Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237
675   controls identifies new susceptibility loci contributing to lung cancer. *Nat Genet* **54**,
676   1167–1177 (2022).

677   29.   Saunders, G. R. B. *et al.* Genetic diversity fuels gene discovery for tobacco and alcohol use.
678   *Nature* **612**, 720–724 (2022).

679   30.   Martin, A. R. *et al.* Human Demographic History Impacts Genetic Risk Prediction across
680   Diverse Populations. *The American Journal of Human Genetics* **100**, 635–649 (2017).

681   31.   Manrai, A. K. *et al.* Genetic Misdiagnoses and the Potential for Health Disparities. *New
682   England Journal of Medicine* **375**, 655–665 (2016).

683   32.   Ochoa, A. genio: Genetics Input/Output Functions. Preprint at https://CRAN.R-
684   project.org/package=genio (2023).

685   33.   Lewis, A. C. F. *et al.* Getting genetic ancestry right for science and society. *Science (1979)*
686   **376**, 250–252 (2022).

687   34.   Kachuri, L. *et al.* Principles and methods for transferring polygenic risk scores across
688   global populations. *Nat Rev Genet* (2023) doi:10.1038/s41576-023-00637-2.

689   35.   US Preventive Services Task Force. Lung Cancer: Screening.
690   *https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-*
691   *screening* (2021).

692   36.   Agency for Healthcare Research and Quality. Clinical Guidelines and Recommendations.
693   *https://www.ahrq.gov/prevention/guidelines/index.html* (2021).

694   37.   Tobacco Use and Dependence Guideline Panel. *US Department of Health and Human
695   Services. (2008). Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and
696   Dependence: 2008 Update.* (US Department of Health and Human Services, Rockville, MD,
697   2008).

698   38.   Krist, A. H. *et al.* Screening for Lung Cancer. *JAMA* **325**, 962 (2021).

699   39.   Ayatollahi, H., Hosseini, S. F. & Hemmat, M. Integrating Genetic Data into Electronic
700   Health Records: Medical Geneticists' Perspectives. *Healthc Inform Res* **25**, 289 (2019).

701   40.   Bourdon, J. L. *et al.* In-vivo design feedback and perceived utility of a genetically-informed
702   smoking risk tool among current smokers in the community. *BMC Med Genomics* **14**, 139
703   (2021).

704   41.   Ramsey, A. T. *et al.* Participatory Design of a Personalized Genetic Risk Tool to Promote
705   Behavioral Health. *Cancer Prevention Research* **13**, 583–592 (2020).

706   42.   Ramsey, A. T. *et al.* Proof of Concept of a Personalized Genetic Risk Tool to Promote
707   Smoking Cessation: High Acceptability and Reduced Cigarette Smoking. *Cancer Prevention*
708   *Research* **14**, 253–262 (2021).

709   43.   Ramsey, A. T. *et al.* Toward the implementation of genomic applications for smoking
710   cessation and smoking-related diseases. *Transl Behav Med* **8**, 7–17 (2018).

711   44.   Chen, L.-S., Baker, T. B., Ramsey, A., Amos, C. I. & Bierut, L. J. Genomic medicine to reduce
712   tobacco and related disorders: Translation to precision prevention and treatment.
713   *Addiction Neuroscience* **7**, 100083 (2023).

714   45.   Chiu, A. *et al.* Most Current Smokers Desire Genetic Susceptibility Testing and Genetically-
715   Efficacious Medication. *Journal of Neuroimmune Pharmacology* **13**, 430–437 (2018).

716   46.   Quaife, S. L., Janes, S. M. & Brain, K. E. The person behind the nodule: a narrative review
717   of the psychological impact of lung cancer screening. *Transl Lung Cancer Res* **10**, 2427–
718   2440 (2021).

719   47.   Quaife, S. L. *et al.* Psychological Targets for Lung Cancer Screening Uptake: A Prospective
720   Longitudinal Cohort Study. *Journal of Thoracic Oncology* **16**, 2016–2028 (2021).

721   48.   Quaife, S. L., Marlow, L. A. V., McEwen, A., Janes, S. M. & Wardle, J. Attitudes towards
722   lung cancer screening in socioeconomically deprived and heavy smoking communities:
723   informing screening communication. *Health Expectations* **20**, 563–573 (2017).

724   49.   Quaife, S. L., McEwen, A., Janes, S. M. & Wardle, J. Smoking is associated with pessimistic
725   and avoidant beliefs about cancer: results from the International Cancer Benchmarking
726   Partnership. *Br J Cancer* **112**, 1799–1804 (2015).

727   50.   Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse Populations:
728   Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603 (2019).

729   51.   Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
730   (2016).

731   52.   Need, A. C. & Goldstein, D. B. Next generation disparities in human genomics: concerns
732   and remedies. *Trends in Genetics* **25**, 489–494 (2009).

733   53.   Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in genome-
734   wide association studies for the most burdensome non-communicable diseases: 2005–
735   2022. *Hum Mol Genet* **32**, 520–532 (2023).

736   54.   Jin, J. *et al.* MUSSEL: Enhanced Bayesian polygenic risk prediction leveraging information
737   across multiple ancestry groups. *Cell Genomics* **4**, 100539 (2024).

738   55.   Zhang, J. *et al.* An ensemble penalized regression method for multi-ancestry polygenic
739   risk prediction. *Nat Commun* **15**, 3238 (2024).

740   56.   Hou, K. *et al.* Admix-kit: an integrated toolkit and pipeline for genetic analyses of admixed
741   populations. *Bioinformatics* **40**, (2024).

57. Bray, M. *et al.* The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence
From Two Treatment Trials. *Nicotine & Tobacco Research* **24**, 1573–1580 (2022).
58. Ramsey, A. T. *et al.* Designing for Accelerated Translation (DART) of emerging innovations
in health. *J Clin Transl Sci* **3**, 53–58 (2019).
59. Proctor, E. *et al.* FAST: A Framework to Assess Speed of Translation of Health Innovations
to Practice and Policy. *Global Implementation Research and Applications* **2**, 107–119
(2022).
60. Scoville, E. A. *et al.* Precision nicotine metabolism-informed care for smoking cessation in
Crohn's disease: A pilot study. *PLoS One* **15**, e0230656 (2020).
61. Chen, L.-S. *et al.* Low-Burden Strategies to Promote Smoking Cessation Treatment Among
Patients With Serious Mental Illness. *Psychiatric Services* **69**, 849–851 (2018).
62. Ramsey, A. T. *et al.* Care-paradigm shift promoting smoking cessation treatment among
cancer center patients via a low-burden strategy, Electronic Health Record-Enabled
Evidence-Based Smoking Cessation Treatment. *Transl Behav Med* (2019)
doi:10.1093/tbm/ibz107.
63. Kaphingst, K. A. *et al.* Comparing models of delivery for cancer genetics services among
patients receiving primary care who meet criteria for genetic evaluation in two
healthcare systems: BRIDGE randomized controlled trial. *BMC Health Serv Res* **21**, 542
(2021).
761
762